Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2012
02/23/2012US20120046242 Molecular activators of the wnt/beta-catenin pathway
02/23/2012US20120046241 Dose of ave5026 for the treatment of venous thromboembolism in patients with severe renal impairment
02/23/2012US20120046240 Method of Producing Hydroxyalkyl Starch Derivatives
02/23/2012US20120046239 Application of american ginseng to enhance neurocognitive function
02/23/2012US20120046238 Coumarin compounds and their use for treating viral infection
02/23/2012US20120046237 Compositions for protection against superficial vasodilator flush syndrome, and methods of use
02/23/2012US20120046236 Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
02/23/2012US20120046235 Conjugates of hydroxyalkyl starch and a protein, prepared by native chemical ligation
02/23/2012US20120046232 Compositions and methods for reducing relapse of addictive behavior
02/23/2012US20120046230 Combination Anticoagulant Therapy With A Compound That Acts As A Factor Xa Inhibitor
02/23/2012US20120046228 Methods for Modulating Ovulation
02/23/2012US20120046226 Combined Treatment of Multiple Sclerosis
02/23/2012US20120046223 Exogenously triggered controlled release materials and uses thereof
02/23/2012US20120046220 Phospholipid depot
02/23/2012US20120046218 Glycosaminoglycan-antagonising mcp-i mutants and methods of using same
02/23/2012US20120045774 Lipoprotein Associated Phospholipase A2, Inhibitors Thereof and Use of the Same in Diagnosis and Therapy
02/23/2012US20120045766 Jarid1b for target gene of cancer therapy and diagnosis
02/23/2012US20120045532 Anticancer Methods Employing Extracts of Gleditsia sinensis Lam
02/23/2012US20120045531 Methods of treating cellulite
02/23/2012US20120045524 Combination therapy with parp inhibitors
02/23/2012US20120045523 Combination of a tlr3 ligand and a chemotherapy agent which acts on the intrinsic "apoptosis" pathway in the treatment of cancer
02/23/2012US20120045519 Use of deoxyelephantopin (det) and analogues thereof for treatment of melanoma
02/23/2012US20120045516 Composition for photodynamic therapy comprising a macromolecular capsule
02/23/2012US20120045513 Polymer-based, sustained release drug delivery system
02/23/2012US20120045510 Tablet sleeve for improved performance
02/23/2012US20120045509 Modified release compositions for dpp-iv inhibitors
02/23/2012US20120045508 Method and composition for administering an nmda receptor antagonist to a subject
02/23/2012US20120045507 Stable soft capsule dosage form for acetylsalicylic acid
02/23/2012US20120045506 Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients
02/23/2012US20120045505 Fixed dose drug combination formulations
02/23/2012US20120045504 oral drug devices and drug formulations
02/23/2012US20120045501 Connexin enhances chemotherapy-included apoptosis in human cancer cells inhibiting tumor cell proliferation
02/23/2012US20120045500 Novel dioxo-imidazolidine derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them
02/23/2012US20120045489 Nano-Emulsion Injection of Vinca Alkaloids and the Preparation Method Thereof
02/23/2012US20120045488 Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
02/23/2012US20120045487 Multiphasic microfibers for spatially guided cell growth
02/23/2012US20120045483 Mannitol and/or Proline for Prevention and Treatment of Ageing Related Symptoms
02/23/2012US20120045482 Policosanol nanoparticles
02/23/2012US20120045478 Method and compositions
02/23/2012US20120045470 Imatinib immunoassay
02/23/2012US20120045465 Cancer antigen helper peptide
02/23/2012US20120045461 Compositions and Methods for Inducing an Immune Response in a Mammal and Methods of Avoiding an Immune Response to Oligonucleotide Agents Such as Short Interfering RNAs
02/23/2012US20120045459 Methods for Treating Autophagy-Related Disorders
02/23/2012US20120045455 Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders
02/23/2012US20120045454 2,4-pyrimidinediamine compounds and their uses
02/23/2012US20120045452 Mnk KINASE HOMOLOGOUS PROTEINS INVOLVED IN THE REGULATION OF ENERGY HOMEOSTASIS AND ORGANELLE METABOLISM
02/23/2012US20120045451 Mnk KINASE HOMOLOGOUS PROTEINS INVOLVED IN THE REGULATION OF ENERGY HOMEOSTASIS AND ORGANELLE METABOLISM
02/23/2012US20120045448 Trp-p8 active compounds and therapeutic treatment methods
02/23/2012US20120045443 Agonist anti-trk-c monoclonal antibodies
02/23/2012US20120045441 Methods of treating lung disease and other inflammatory diseases
02/23/2012US20120045439 Tumor markers and methods of use thereof
02/23/2012US20120045434 Combination therapy
02/23/2012US20120045433 Combination therapy
02/23/2012US20120045430 Dendrimer-like modular delivery vector
02/23/2012US20120045429 Methods and Agent for Modulating the RNA Polymerase II-Histone Surface
02/23/2012US20120045425 Delta 4, 5 glycuronidase compositions and methods related thereto
02/23/2012US20120045412 Cycloalkylidene and heterocycloalkylidene inhibitor compounds
02/23/2012US20120045395 MicroRNAs In Idiopathic Pulmonary Fibrosis
02/23/2012US20120045390 Composition and Methods for the Diagnosis and Treatment of Tumor
02/23/2012US20120045389 Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
02/23/2012US20120043242 Medicinal cannabis fatty foodstuff
02/23/2012DE102010034699A1 Pyrimidinderivate Pyrimidine derivatives
02/23/2012CA2855690A1 Oligonucleotide chelate complexes
02/23/2012CA2845241A1 Anti-viral carbamimidothioic acid esters
02/23/2012CA2844292A1 Devices and methods for intravaginal delivery of drugs and other substances
02/23/2012CA2844109A1 Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
02/23/2012CA2841217A1 Novel sulfonamide compounds for inhibition of metastatic tumor growth
02/23/2012CA2809028A1 Nicotinic receptor compounds
02/23/2012CA2809022A1 Phospholipid depot
02/23/2012CA2808866A1 Compositions and methods for treatment of cystic fibrosis and diseases associated with aberrant protein cellular processing
02/23/2012CA2808798A1 Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
02/23/2012CA2808679A1 Novel phytochemicals from extracts of maple syrups and maple trees and uses thereof
02/23/2012CA2808678A1 Fused ring compound for use as mineralocorticoid receptor antagonist
02/23/2012CA2808660A1 Treatment of cognitive disorders associated with abnormal dendritic spines using pkc activators
02/23/2012CA2808630A1 Methods of treating mild cognitive impairment (mci) and related disorders
02/23/2012CA2808628A1 Ophthalmic formulations of squalamine
02/23/2012CA2808626A1 Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol
02/23/2012CA2808624A1 Lipidated immune response modifier compound compositions, formulations, and methods
02/23/2012CA2808622A1 Method of stabilizing and sterilizing peptides or proteins
02/23/2012CA2808543A1 Pyrrolopyrimidine compounds and uses thereof
02/23/2012CA2808540A1 Pyrimidine derivatives as fak inhibitors
02/23/2012CA2808492A1 Antifungal agents and uses thereof
02/23/2012CA2808489A1 Anti-microbial compositions
02/23/2012CA2808407A1 Ep2 or ep4 agonists for treating corneal haze
02/23/2012CA2808307A1 Method of activating regulatory t cells with alpha-2b adrenergic receptor agonists
02/23/2012CA2808291A1 Compounds and methods for the treatment or prevention of flaviviridae viral infections
02/23/2012CA2808210A1 Composition comprising tetracyclic compound
02/23/2012CA2808165A1 Compounds and therapeutic applications related to inhibition of dendritic cell immunoreceptor (dcir) activity and signaling events
02/23/2012CA2808131A1 Nutritional compositions comprising chitin microparticles
02/23/2012CA2808019A1 Particulate substances comprising ceramic particles for delivery of biomolecules
02/23/2012CA2807776A1 1,5-diphenyl-penta-1,4-dien-3-one compounds
02/23/2012CA2807419A1 Diketones and hydroxyketones as catenin signaling pathway activators
02/23/2012CA2807405A1 Testosterone solutions for the treatment of testosterone deficiency
02/23/2012CA2807364A1 Oxadiazole inhibitors of leukotriene production
02/23/2012CA2807307A1 Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
02/23/2012CA2807222A1 Combination anti - cancer therapy
02/23/2012CA2807218A1 Novel combination therapy for the treatment of cancer
02/23/2012CA2807089A1 2-(arylamino)-3h-imidazo[4,5-b]pyridine-6-carboxamide derivatives and their use as mpges-1 inhibitors
02/23/2012CA2807086A1 Disubstituted tetrahydrofuranyl compounds as antagonists of the bradykinin b1 receptor
02/23/2012CA2806634A1 Substituted cyclic carboxamide and urea derivatives as ligands of the vanilloid receptor
1 ... 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 ... 7860